NASDAQ:EVAX
READ THE FULL EVAX RESEARCH REPORT
Evaxion (NASDAQ:EVAX) is a clinical stage company that is making AI useful in the current environment by using the technology to develop new cancer-fighting vaccines. The company notes that it has demonstrated that it can identify, through the company’s AI models, novel targets within days, rather than the traditional years it commonly takes with standard drug discovery methods. The use of AI also allows the company to decrease the risk of failure as the technology filters out those results that may result in low efficacy or unacceptable toxicity.
Company management announced that it was adjusting its ADS ratio from 1 ADS representing 10 ordinary shares to 1 ADS representing 50 ordinary shares. This move creates more investment opportunities for investors who may require a minimum price to invest in the company. As a result, we are adjusting our price target to $19.75 per share in order to account for the adjustment.
Late last year, the company announced positive preclinical data from its ongoing cytomegalovirus (CMV) vaccine program named EVX-V1. According to the CDC, nearly 1 in 3 children is already infected with CMV by age 5 and over half of adults have been infected with CMV by age 40. Adults usually have no or mild symptoms but in babies it can cause serious health problems that can last into adulthood. There are no current vaccines available for CMV. The data presented by Evaxion demonstrated that the antigens identified with Evaxion’s AI-Immunology platform effectively trigger targeted immune responses, including induction of both CMV reactive B and T cells. To further enhance vaccine effectiveness, Evaxion noted it additionally designed a proprietary prefusion gB antigen, a well-established CMV vaccine component known to offer partial virus neutralization. New preclinical data presented by the company confirms that Evaxion’s proprietary gB antigen successfully induced a specific immune response comparable to that of the conventional gB antigen.
In addition, the company reminded investors that its ongoing Phase 2 trial of its personalized cancer vaccine, EVX-01, triggered a 79% tumor-specific response, a substantial increase from the 58% response rate seen in the Phase I trial. As we’ve talked about in previous reports, the AI-Immunology platform of Evaxion showed the promise of improving treatment for patients by being able to “learn” from previous trials and improve upon the treatment as it moves along the approval process. These results are further confirmation of the vast potential that this platform has and illustrate why we continue to have a very positive view on the company.
We continue to be excited about the investment opportunities offered by EVAX. In our view, these announcements are the tip of the iceberg of what the AI platforms developed by Evaxion can achieve and positive news will continue to come out as we move forward. We suggest investors investigate EVAX further and consider investing, as we believe the company is at an inflection point that is the start of sustained uptrend.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
